Dara Pharmaceutical Equipment’s Post

The Pulmonary Suite of data models was used to successfully identify disease areas, useful #biomarkers and #endpoints that best demonstrated treatment efficacy for a novel drug. Missed this case study? Catch up now at https://bit.ly/423yl5Q. #clinicaltrials #biotech #pharma #biopharma #respiratoryclinicaltrials #datamodels #data #datascience

Targeting specific #subpopulations in clinical trials can reveal crucial insights. In our latest blog, Jim Bolognese discusses three key hypotheses for trials targeting specific subpopulations and different testing strategies. 👉 Learn more: https://hubs.ly/Q02Bkwxr0 #ClinicalTrials #Subpopulations #Biomarkers #HypothesisTesting #StatisticalPower #TrialDesign #Pharma #Biotech

The approval of 55 novel drugs in 2023 signifies a return to normalcy following a notable decline in 2022.This diverse range of approvals include small molecules, #proteins, and #oligonucleotides, reflecting the ongoing innovation and advancement in the #pharmaceutical industry. From mAbs to RNA-based therapies, each category represents groundbreaking progress in treating a wide array of diseases. Dive into our full report “Top 10 #Life Sciences Trends” which offers a detailed overview of significant #trends from 2023 and provides insights into the industry's future for 2024. https://lnkd.in/dkXhHYCX #DrugApproval #PharmaInnovation #HealthcareAdvancements #Biotechnology #MedicalResearch #PatientCare #HealthcareInnovation #newtherapies #2023Milestones

Initially, I saw the reports of #Pfizer's #danuglipron and #SunPharma's #utreglutide and thought we were witnessing another PD-L1 or TNF-inhibitor scenario. I believed they might be late to catch the bus as Novo and Lilly already captured a significant market. However, after reviewing #Roche's press releases and their significant investment in metabolic disorders, I realised the market potential is still unfolding. By the 2030s, this market might be much larger - with nearly 50% of the world's population getting impacted because of #obesity. Roche is making substantial investments in metabolic disorders, boasting a robust pipeline that includes CT-388, CT-996, and CT-868. Their commitment is paying off, with Roche's stock price soaring 10% in the last five days, thanks in part to the positive results of CT-996. The future looks incredibly promising for GLP-1 agonists and metabolic disorder treatments. Exciting Times Ahead for GLP-1 Agonists! #Pharmaceuticals #Biotech #GLP1Agonists #MetabolicDisorders #Roche #Innovation #Healthcare

Thoughts on this? >> AviadoBio and Astellas Ink Potential $2.5B+ Deal for Frontotemporal Dementia Candidate - Inside Precision Medicine >> Comment below! >>> lqventures.com #pharma #pharmaceutical #competitivemarketing #healthcare #biotech

Choosing the right trial design approach reduces patient burden, costs and timelines. With the new #Pulmonary Suite, #respiratory studies can be de-risked to speed up the delivery of new medicines to people with unmet need. Learn more at https://lnkd.in/gVkJFWZs. #clinicaltrials #biotech #pharma #COPD #IPF 

Thoughts on this? >> PTC touts Phase 2 biomarker data for Huntington’s drug, showing dose-dependent effect at one year >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #biotech #healthcare #pharma

Thoughts on this? >> PTC touts Phase 2 biomarker data for Huntington’s drug, showing dose-dependent effect at one year >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech

Thoughts on this? >> AviadoBio and Astellas Ink Potential $2.5B+ Deal for Frontotemporal Dementia Candidate - Inside Precision Medicine >> Comment below! >>> lqventures.com #competitivemarketing #healthcare #pharma #pharmaceutical #biotech

Have you noticed that the disease of liquidity has multiple names? Yes, the disease of liquidity has many names, such as: Hereditary bleeding, Hemophilia, Hemorrhagic, and Bleeding. But they all refer to the same disease. On World Hemophilia Day, Trillioni Pharma is proud to support the hemophilia community by making it easier to manufacture medicine for patients in need. Follow us and learn more about the disease and the medicine. #worldhemophiliaday #hereditarybleeding #pharmamarketing #pharmaceuticalmanufacturing #pharmalogistics #pharmaindustry #innovationhub #pharma #pharmaceuticals